Karuna Therapeutics, Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q2 2018 to Q4 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Karuna Therapeutics, Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q2 2018 to Q4 2023.
- Karuna Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending December 31, 2023 was -$111M, a 46% decline year-over-year.
- Karuna Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending December 31, 2023 was -$430M, a 54.1% decline year-over-year.
- Karuna Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$430M, a 54.1% decline from 2022.
- Karuna Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$279M, a 93.4% decline from 2021.
- Karuna Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$144M, a 111% decline from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)